Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-118 in Relapsed or Refractory Hematological Malignancies
NCT04771572Phase 1Recruiting
- Sponsor
- Newave Pharmaceutical Inc.
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LP-118 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelofibrosis (MF) and 9 more (2 arms), sponsored by Newave Pharmaceutical Inc. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose or Optimal Biological Dose at 28 days and 3 more. Started May 2022; status: recruiting.
02
Drugs
LP-118
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)myelofibrosis (MF)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT04771572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771572.